Providing Computational Insights into Cardiac Xenotransplantation
XENOSIM aims to advance cardiac xenotransplantation by developing high-resolution simulations to understand porcine heart compatibility and improve surgical outcomes.
Projectdetails
Introduction
We are at the dawn of a new age in medicine, marked by the first pig-to-human heart transplant. Xenotransplantation has long been a dream for clinicians and now, due to rapid progress in gene editing, is becoming a reality.
Challenges in Xenotransplantation
To overcome immediate rejection, barriers of immunity and infection have to be addressed. However, achieving long-term success requires a deep understanding of the physiological and mechanical challenges introduced by the anatomically dissimilar xenotransplants.
Objectives of XENOSIM
XENOSIM aims to address these challenges by providing fundamental clinical insights into the nascent field of cardiac xenotransplantation through the development and application of novel high-resolution, higher-order, multiphysics simulation methods.
Current Limitations
Tremendous progress has been made in biomedical imaging; nonetheless, a multitude of physical phenomena relevant to xenotransplantation are not available for experimental observation. In silico studies are uniquely placed to provide insights into the haemodynamic disruption caused by replacing a human heart with an anatomically dissimilar one.
Development of Porcine Cardiac Xenotransplant Models
XENOSIM is targeting the establishment of the first family of porcine cardiac xenotransplant models that can provide clinically significant insights into:
- The haemodynamic compatibility of porcine donor hearts
- The impact of surgical approach
- The consequence of pathologies
To provide these novel insights requires new coupled simulation approaches.
New Simulation Methods
Accordingly, the second goal of XENOSIM is to create a new class of monolithic finite volume fluid-electro-solid interaction methods, which can provide predictions in clinically relevant timescales through the exploitation of hybrid CPU-GPU systems.
Impact of XENOSIM
XENOSIM will establish the new field of computational cardiac xenotransplantation. Furthermore, the novel numerical methods established by XENOSIM are expected to impact a broad range of fields well beyond the project end.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.999.410 |
Totale projectbegroting | € 1.999.410 |
Tijdlijn
Startdatum | 1-1-2024 |
Einddatum | 31-12-2028 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLINpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Advanced human models of the heart to understand cardiovascular diseaseHeart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Using CARDIac simulations to run in-silicO clinical TRIALSThis project aims to develop a GPU-accelerated computational platform for simulating cardiac pathologies and device responses, integrating uncertainty quantification to enhance in-silico clinical trials. | ERC Starting... | € 1.499.423 | 2022 | Details |
Computationally and experimentallY BioEngineeRing the next generation of Growing HEARTsG-CYBERHEART aims to develop innovative experimental and computational methods for creating adaptable bioengineered hearts to improve treatment for congenital heart disease. | ERC Starting... | € 1.497.351 | 2022 | Details |
Surgical optogenetic bioprinting of engineered cardiac muscleLIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart. | ERC Starting... | € 1.499.705 | 2023 | Details |
Development of novel 3D vascularized cardiac models to investigate Coronary Microvascular DiseaseThe 3DVasCMD project aims to develop a 3D vascularized cardiac model using iPSC technology to study coronary microvascular disease and identify therapeutic targets for improved cardiovascular health. | ERC Starting... | € 1.496.395 | 2022 | Details |
Advanced human models of the heart to understand cardiovascular disease
Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.
Using CARDIac simulations to run in-silicO clinical TRIALS
This project aims to develop a GPU-accelerated computational platform for simulating cardiac pathologies and device responses, integrating uncertainty quantification to enhance in-silico clinical trials.
Computationally and experimentallY BioEngineeRing the next generation of Growing HEARTs
G-CYBERHEART aims to develop innovative experimental and computational methods for creating adaptable bioengineered hearts to improve treatment for congenital heart disease.
Surgical optogenetic bioprinting of engineered cardiac muscle
LIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart.
Development of novel 3D vascularized cardiac models to investigate Coronary Microvascular Disease
The 3DVasCMD project aims to develop a 3D vascularized cardiac model using iPSC technology to study coronary microvascular disease and identify therapeutic targets for improved cardiovascular health.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
ADAM-X-HeartUtrecht Preclinical en Medical-X ontwikkelen ADAM-X-Heart, een proefdiervrije simulator voor hartchirurgische training, om de kwaliteit, capaciteit en kosten van opleidingen te verbeteren. | Mkb-innovati... | € 329.735 | 2021 | Details |
Engineering a living human Mini-heart and a swimming Bio-robotThe project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease. | EIC Pathfinder | € 4.475.946 | 2022 | Details |
High-throughput ultrasound-based volumetric 3D printing for tissue engineeringSONOCRAFT aims to revolutionize myocardial cell construct bioprinting by combining rapid volumetric printing with ultrasonic manipulation to create functional cardiac models for drug testing and disease research. | EIC Pathfinder | € 2.999.625 | 2025 | Details |
Bringing 3D cardiac tissues to high throughput for drug discovery screensDeveloping a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability. | EIC Transition | € 1.457.500 | 2023 | Details |
Simultaneous Multiparametric MEA based platform for in-vitro chronic cardiotoxicity assessment with live-cell fluorescence imaging and electrophysiology.SiMulTox develops a novel platform for simultaneous long-term assessment of functional and structural cardiotoxicity, aiming to enhance drug safety evaluation and reshape the in-vitro testing market. | EIC Transition | € 786.875 | 2022 | Details |
ADAM-X-Heart
Utrecht Preclinical en Medical-X ontwikkelen ADAM-X-Heart, een proefdiervrije simulator voor hartchirurgische training, om de kwaliteit, capaciteit en kosten van opleidingen te verbeteren.
Engineering a living human Mini-heart and a swimming Bio-robot
The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.
High-throughput ultrasound-based volumetric 3D printing for tissue engineering
SONOCRAFT aims to revolutionize myocardial cell construct bioprinting by combining rapid volumetric printing with ultrasonic manipulation to create functional cardiac models for drug testing and disease research.
Bringing 3D cardiac tissues to high throughput for drug discovery screens
Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.
Simultaneous Multiparametric MEA based platform for in-vitro chronic cardiotoxicity assessment with live-cell fluorescence imaging and electrophysiology.
SiMulTox develops a novel platform for simultaneous long-term assessment of functional and structural cardiotoxicity, aiming to enhance drug safety evaluation and reshape the in-vitro testing market.